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1. Introduction
Understanding the effect of renal transporters on the distribution of drugs, metabolites, and
endogenous compounds (e.g., biomarkers for renal toxicity and physiological regulators) are
important in safety assessment studies [1]. Drugs (and their metabolites) that preferentially
distribute into the kidney may have a greater potential to induce renal toxicity because these
compounds may accumulate in the cells surrounding/forming the renal tubules. This dispo‐
sition may not be deduced by simply sampling plasma; therefore, sampling kidney tissue in
addition to plasma is important for measuring concentrations of drugs when renal toxicity is
observed in animals. In human safety assessment, sampling of kidney is not generally feasible;
therefore, the utility of qualified tissue-, serum- and/or urine-specific biomarkers may help to
extrapolate between animal tissue and human exposures.
This chapter will review the role of renal transporters and biomarkers in the safety assessment
of drug candidates. Membrane permeability and types of drug transporters will be introduced
with focus on specific renal transporters. Examples of cause-effect relationships between renal
transporters and toxicity will be discussed. The effect of drugs on the ability of renal trans‐
porters to regulate the disposition of endogenous compounds involved in maintaining
homeostasis will be discussed. In addition, a case example on the effect of a proprietary drug
candidate on a classical biomarker of renal safety will be highlighted where an increase of this
biomarker via inhibition of a renal transporter was determined to be benign and not the
consequence of renal toxicity. Finally, we will highlight the recent qualification of novel
diagnostic renal urinary biomarkers that outperform the traditional renal biomarkers, serum
creatinine (sCr) and/or blood urea nitrogen (BUN) in monitoring renal injury in preclinical
(rat) studies. We will also highlight use of selected novel renal biomarkers in rat and dog
studies with the paradigm renal toxicant, cisplatin.
© 2013 Ward et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Transport through cellular barriers
Molecules cross cellular barriers by three main pathways: (1) passive diffusion across the cell
membranes; (2) passive diffusion between adjacent cells; and (3) carrier-mediated transport
(Fig. 1). Lipophilic molecules cross the cells membrane by transcellular diffusion. By contrast,
hydrophilic molecules that are not recognized by a carrier cannot partition into the hydro‐
phobic membrane and thus traverse the epithelial barrier via the paracellular pathway.
Hormones and certain immune system molecules can utilize membrane invaginations for
transport across the cell (e.g. via caveolae). All other compounds must interact with carrier
proteins, either in a facilitated manner (down the concentration gradient) or via “active”
transport, potentially against a concentration gradient. The driving force to allow active
transport may include the use of ATP hydrolysis, pH gradients, or electrogenic properties of
the cell. [2]
Transporters depicted in Pathway ④ (Fig. 1) efflux compounds from cell into the lumen or
blood and are thought to act as a cellular defender to prevent xenobiotics from either entering
the cells or endogenous waste products from accumulating in the cells. These types of
transporters are referred to as efflux transporters. With respect to pharmaceutical compounds,
clinically relevant transporters are members of the ATP-binding cassette (ABC) superfamily
membrane bound transporters [3]. P-glycoprotein (P-gp) is the most well characterized ABC
transporter [4, 5]. Other efflux transporters such as multidrug resistance-associated protein
(MRP) members in proximal tubular cells function as an extrusion pump for organic anions
from the apical membrane, especially large and hydrophobic organic anions such as gluta‐
thione and glucuronide conjugates [6].
Transporters depicted in Pathway ③ (Fig. 1) facilitate transport of nutrients (e.g., amino acids
and glucose) and drugs into cells. These types of transporters are referred to as uptake or influx
transporters. For nutrients, uptake transporters are essential for reabsorbing glucose from the
tubule lumen into the systemic circulation. The importance of these types of transporters and
the impact of interrupting their function on safety assessment will be further discussed in
Section 5.
For pharmaceutical compounds, members of the Solute Carrier (SLC) superfamily of mem‐
brane transport proteins (depicted in Pathway ⑤, transport an extraordinarily diverse set of
solutes, including both charged and uncharged organic molecules as well as inorganic ions)
have wide implications on human physiology, pathology, and in multiple therapeutic areas
[7]. Examples of SLC transporters (Fig. 2) include organic cation transporters (OCT) and
organic anion transporters (OAT). Renal transporters (e.g., OAT and OCT) allow the entry of
drugs (with low passive transcellular permeability) through the basolateral membrane into
the tubule cells, which leads to elimination of the drug into urine by transport of the drug
through the apical membrane by either SLC or efflux transporters (i.e., tubular secretion).
Interestingly, SLC transporters expressed on the apical or luminal membrane (e.g., novel
organic cation transporters (OCTN) and OAT4) may also play a role in tubular reabsorption,
process by which compounds are removed from the tubular fluid and transported into the
blood [8].
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3. Drug transporters in the kidney
The kidney is responsible for clearance of many drugs including polar hydrophilic compounds
such as ß-lactam antibiotics and non-steroidal anti-inflammatory drugs [9]. Polar compounds
may be actively taken up by the proximal tubule cells through a variety of transporters
Figure 1. Routes of translocation through cellular barriers. ① Lipid soluble compounds can permeate through the epi‐
thelium by simple passive diffusion (transcellular route). ②Small molecular weight compounds such as CO2 can per‐
meate through the tight junctions (TG) between cells (paracellular route). ③Facilitative transport (e.g., uptake of
amino acids) occurs via a transport carrier down the concentration gradient of the solute. ④Transport can also occur
via a carrier, but against the concentration gradient of the solute. In the case of efflux transporters such as P-glycopro‐
tein (P-gp), ATP-hydrolysis is the driving force for this transport. ⑤Uptake carriers such as the organic anion or organic
cation transporters can also transport substances against a concentration gradient. The driving force is dependent on
the particular transporter but can be pH-dependent or electrogenic. ⑥Some hormones are transported through the
epithelium via receptor-mediated transcytosis. The ligand binds to a cell surface receptor, which cause an invagination
in the membrane. This invagination is internalized and carried to the opposite membrane where the ligand is then
released ([2]; reproduced with permission).
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including OCT2, OAT1 and 3 (Fig. 2, Table 1). Once taken up into the proximal tubule cells,
compounds generally must efflux out of the cells into the urine by a different set of transporters
including MRP2, P-gp, and MRP4 (i.e., facilitation of tubular secretion). In the human kidney,
the order of transporter mRNA expression (highest to lowest) is OAT1, OAT3, P-gp, MRP2,
and OCT2 [10].
Recently, the importance of renal transporters called multidrug and toxin extrusion proteins
(MATE), which are expressed in the apical (luminal) membrane of proximal tubule epithelial
cells, have been highlighted [11]. Functionally, MATEs act as efflux transporters, thereby
mediating the excretion of metabolic waste products and xenobiotics. Two isoforms, MATE1
and 2, have been identified, and, so far, only a limited number of substrates, including clinically
used drugs such as metformin and cimetidine, are known [12].
Figure 2. Select drug transporters located in the kidney predicted to play a role in drug distribution and elimination.
Influx transporters located on the basolateral or blood side of the kidney tubule cells include the organic anion trans‐
porters OAT1 and 3, and the organic cation transporter OCT2. Efflux transporters located on the basolateral side in‐
clude multiple members of the multidrug resistance protein family such as MRP1 and MRP6. Efflux transporters
located on the apical or luminal side of the tubule membrane which pump drugs from the interior of the tubule cell
into the tubular fluid include P-gp, MRP2 and MRP4 ([2]; reproduced with permission).
Compounds may be reabsorbed from the tubular fluid back into the tubule cells or cleared
from the body. The interplay between various transporters located on the basolateral (blood)
or apical (luminal) side dictates the overall renal clearance of a compound. As with the liver,
renal transporters can therefore be a site of potential drug-drug interactions (DDI). Inhibi‐
tion of the basolateral transporters (by the primary compound, metabolites, or a co-adminis‐
tered compound) can lead to increased exposure of the drug and longer half-lives in the
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systemic circulation. Inhibition of renal uptake of some drugs may actually induce toxicity
by inhibiting their renal excretion. For example, severe methotrexate toxicity due to an in‐
crease in serum concentrations was observed in patients after co-administration with probe‐
necid which inhibited OAT1 and MRP, and consequently the tubular secretion of
methotrexate [13, 14]. Inhibition of the luminal efflux transporters, again by either the com‐
pound itself or a co-administered drug, can also cause an increase in systemic exposure if
the basolateral transporters are able to transport the compound back into the systemic circu‐
lation. Alternatively, inhibition of the luminal efflux transporters can cause a compound to
be “trapped” in the cell which may lead to renal toxicity [2].
Protein/Gene Substrates Inhibitors References
OCT2/SLC22A2 cimetidine, metformin, MPP+,quinine TEA
cimetidine, clonidine, procainamide,
quinine [15, 16]
OAT1/SLC22A6 adefovir,para-aminohippurate, furosemide
furosemide, indomethacin,
probenecid, urate [17, 18]
OAT3/SLC22A8 benzylpenicillin, furosemide,methotrexate, pravastatin
gemfibrozil, indomethacin,
probenecid, salicylate [17, 19]
P-gp/ABCB1
digoxin, daunorubicin, doxorubicin,
fexofenadine, irinotecan, paclitaxel,
quinidine, saquinavir, verapamil
cyclosporine A, elacridar, quinidine,
valspodar, verapamil [4, 5, 20, 21]
MRP1/ABCC1
daunorubicin, etoposide,
methotrexate, glutathione,
glucuronide and sulfate conjugates,
vincristine
delavirdine, efavirenz, MK571,
probenecid [6, 20]
MRP2/ABCC2 Similar to MRP1, cisplatin,methotrexate
delavirdine, efavirenz, MK571,
probenecid [20, 22, 23]
MRP4/ABCC4
adefovir, azidothymidine
monophosphate, prostaglandins,
methotrexate
indomethacin, ketoprofen [24, 25]
Table 1. Substrates and inhibitors of select renal transporters ([2]; partially reproduced with permission)
4. Importance of plasma sampling and understanding drug disposition in
renal tissue during safety assessment
Compound-induced toxicities can be better extrapolated from animals to humans when these
comparisons are based on toxicokinetics instead of dose alone [26]. For example, the safety
margin that is based on the ratio of the animal exposure at the no observed adverse effect level
(NOAEL) to human exposure at the efficacious dose is a key predictor of human safety risk.
To calculate this safety margin, the animal and human exposure is determined by analyzing
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drug and metabolite(s) concentrations in plasma, which is the most practical and widely
accepted way of assessing this risk. However, most safety issues are not due to drug plasma
concentration but due to concentration of drug in various organs/tissues.
Sampling plasma and extrapolating this exposure to organs or tissues assumes that 1) con‐
centration of drug in plasma is in equilibrium with concentrations in tissues, 2) changes in
plasma drug concentrations reflect changes in tissue drug concentrations over time, and 3)
distribution of drug and its metabolites are not affected by cells (e.g., drug transporters and
enzymes) that protect many of these tissues [27]. Drug transport into tissues may not be a
passive process and may depend on drug transporters, and thus these assumptions may result
in an inaccurate assessment of target organ exposure to drug and/or metabolites. Even without
a drug being a substrate for a drug transporter, lysosomal trapping of weak bases (e.g., liver
and lung) or accumulation in membranes (e.g., muscle) can occur that can subsequently give
rise to preferential distribution of the drug and its metabolites. For more details, refer to http://
www.intechopen.com/books/toxicity-and-drug-testing/toxicokinetics-and-organ-specific-
toxicity [27].
If the compound enters tubular cells via uptake transporters (e.g. OCT2, OAT1, OAT3), but
not effluxed (into luminal fluid or urine), very high compound concentrations can occur in the
renal cells/tissue. A convincing cause-effect relationship exists between uptake of renal
toxicants via transporters and associated renal toxicity where co-administration of probenecid
(inhibits renal uptake of organic anions) or either cimetidine or imatinib (inhibits renal uptake
of organic cations) may reduce renal toxicity (by limiting uptake). For example, co-adminis‐
tration of cisplatin with imatinib prevents cisplatin-induced renal toxicity by inhibiting influx
via OCT2 [28]. Another example is co-administration of cephaloridine with probenecid lowers
the potential risk of cephaloridine-induced renal toxicity by inhibiting the OAT1-mediated
transport of cephaloridine into the proximal tubule cell [29].
Influx transporter OAT1 (minor contribution by OAT3) is involved in the renal safety of
acyclic nucleotide phosphonates (adefovir, cidofovir, and tenofovir), which are eliminated
predominantly  into  the  urine  [30-32].  The  dose-limiting  toxicity  for  acyclic  nucleotide
phosphonates is renal failure, particularly for adefovir and cidofovir which may accumu‐
late in the kidney [33, 34]. Patients treated with tenofovir exhibit a lower incidence of renal
dysfunction at doses used to treat HIV compared to adefovir and cidofovir [35, 36]. In vitro
studies showed that cells expressing human OAT1 showed enhanced toxicity to adefovir
and cidofovir [500-fold) compared to cells that do not express OAT1 [37]. Unlike adefovir
and cidofovir,  tenofovir  is  less  nephrotoxic  to  OAT1-expressing cells  [38].  Additional  in
vitro studies  demonstrated that  OAT1 inhibitors  such as  nonsteroidal  anti-inflammatory
drugs, protect OAT1-expressing cells from adefovir- and cidofovir-induced cytotoxicity by
preventing their cellular accumulation [39].
Efflux transporters in the kidney also play a potential role in the safety of a drug by pumping
the drug out of the tubule cell and into the blood or urine (tubular fluid) and preventing the
accumulation of the drug in the tubule cell. For example, the efflux transporters, MRPs, may
be another crucial factor in the renal accumulation of acyclic nucleotide analogs (in addition
to the uptake) and subsequent nephrotoxicity. Interestingly, renal toxicity in patients is
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observed with tenofovir when co-administered with an inhibitor of MRP2, ritonavir [40].
However, tenofovir is also a substrate for MRP4 that may not be inhibited by ritonavir [41,
42]. Other members of the MRP family (MRP5 and 8) may also be involved in the transport of
acyclic nucleotide analogs [43]. Transport of adefovir and cidofovir was not observed in the
membrane vesicles expressing human MRP2 and BCRP; furthermore, transport of adefovir
and tenofovir but not cidofovir was observed only in the membrane vesicles expressing MRP4
[41]. To support these in vitro observations, the kidney accumulation of adefovir and tenofovir
was significantly greater in Mrp4 knockout mice; however, there was no change in the kinetic
parameters of cidofovir in these mice [41].
Another example of the relationship between efflux transporters and renal safety is MATE and
platinum drugs. MATE can effectively mediate the transport of oxaliplatin, but not that of
cisplatin [44]. Interestingly, oxaliplatin is effectively transported into renal proximal tubular
cells by OCT2 but does not accumulate due to MATE-mediated renal extrusion, which may
be the reason that oxaliplatin is much less nephrotoxic than cisplatin. Therefore, the interplay
between renal OCTs and MATEs may influence the pharmacokinetics of platinum compounds
and may critically determine the severity of platinum-associated adverse events [45].
This idea of reducing tubule exposure or even renal tissue half-life and consequently increasing
the safety of drugs is also emphasized by studies investigating differences in renal safety of
bisphophonates. In a rat model, zoledronic acid, but not ibandronate, induces progressive
renal toxicity [46]. Ibandronate has a terminal renal tissue half-life of 24 days [47], whereas the
renal tissue half-life of zoledronic acid (150–200 days) does not allow enough time for repair
of renal damage [48]. Renal excretion is the only route of elimination of bisphosphonates.
Interestingly, studies in rats demonstrated that alendronate is actively secreted by an unchar‐
acterized renal transport system, and not by the anionic or cationic renal transport systems [49].
Understanding the tissue distribution and the substrate specificity for drug transporters can
significantly aid safety assessment. In addition, this increased understanding can support the
development of drugs with improved safety [1, 27] and/or a different route of administration
that avoids distribution to the organ(s) where the compound-induced toxicity occurs. For
example, an aerosolized form of [14C]-cidofovir (dose-limiting toxicity is nephrotoxicity)
administered to mice (via inhalation) results in the prolonged retention of radiolabeled drug
in the lungs (site of initial viral replication) at levels exceeding those in the kidneys [34]. In
contrast, subcutaneous injection produces much higher concentrations of [14C]-cidofovir in the
kidneys compared to the lungs [34]. Possibly in the future, the disposition of drug candidates
may be directed by targeting specific drug transporters in organs like the kidney to signifi‐
cantly improve the renal safety of the drug candidate.
5. Importance of renal transporters in the regulation of homeostasis
Renal transporters regulate disposition of endogenous compounds that control homeostasis
of a physiological system. Therefore, alteration in the activity of renal transporters by drugs
may be a method to treat disease but also unexpected changes to the activity of these trans‐
Renal Transporters and Biomarkers in Safety Assessment
http://dx.doi.org/10.5772/54857
159
porters may induce adverse effects. For example, Na+-dependent dicarboxylate transporters
and OATs are involved in the disposition of dicarboxylates which are important regulators of
the renovascular system; therefore, these renal transporters may play an important role in the
maintenance of blood pressure [50]. Another example is the role of renal transporters in the
regulation of serum uric acid levels where renal transporters of uric acid like GLUT9 (SLC2A9)
may be a target for treatment of gout [51].
Recently, renal glucose transport has become a very active target for drug development. The
kidney reabsorbs 99% of the glucose that filters through the renal glomeruli [52]. Approxi‐
mately 90% of the glucose is reabsorbed by the low affinity, high capacity sodium-dependent
glucose cotransporter (SGLT) 2 in the proximal tubules. The remaining glucose is reabsorbed
by the high affinity, low capacity transporter, SGLT1 (expressed in the segment 3 of the
proximal tubule). Co-transport with sodium enables movement of glucose by SGLTs against
a concentration gradient, with the sodium gradient maintained by the Na+/K+ ATPase pump.
Individuals with SGLT2 mutations (e.g., familial renal glucosuria or FRG) have persistent yet
benign renal glucosuria [53]. Similar to the effect observed with FRG, novel drugs are being
developed to reduce glucose reabsorption by inhibiting SGLT2. One such example, dapagli‐
flozin is a selective SGLT2 inhibitor that is being developed for the treatment of type 2 diabetes
mellitus, a disorder characterized by elevated blood glucose [54]. In diabetic rat models,
dapagliflozin has been shown to decrease serum glucose concomitant with glycosuria. Similar
effects have been observed in clinical trials with decreased hemoglobin A1c, fasting plasma
glucose, postprandial glucose, and body weight in patients with type 2 diabetes.
6. Importance of renal drug transporters in the disposition of a classical
biomarker in renal safety assessment
Creatinine is a breakdown product of creatine phosphate in muscle that is cleared by glomer‐
ular filtration and tubular secretion, and is routinely used as a diagnostic biomarker of renal
function. For example, sCr can be used to estimate creatinine clearance which is then used to
calculate glomerular filtration rate (GFR). Generally, a doubling of sCr suggests a 50%
reduction in GFR.
Yet, sCr measurement as an indicator of compound-induced renal toxicity is often unreliable
as sCr levels can be altered by changes in the levels of muscle mass and/or dietary protein. For
example, sCr levels are often less reliable for detecting impaired GFR in the elderly, females,
those with chronic illness associated with muscle wasting, African Americans, amputees, and
vegans; various equations can be used to adjust for some of these factors to obtain a more
reliable estimation of GFR [55, 56].
Creatinine is actively secreted by organic cation transporters including OCT2 and MATE
which results in an overestimation of GFR by up to 40% [57-60]. For example, a drug that
inhibits OCT2 can cause an increase in sCr levels independent of renal impairment [61].
Increased sCr levels in such cases typically stabilize over time and are not considered clinically
relevant.
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sCr increases due to OCT2 and MATE inhibition show a characteristic temporal pattern. When
a drug is administered over several days, creatinine levels increase quickly, reach a plateau,
and return to baseline levels shortly after drug discontinuation. This pattern is illustrated in
the following case example from a clinical study with Compound A (Fig. 3). Subjects were
administered placebo or one of three dose levels of Compound A daily for 2 weeks. sCr levels
were unchanged for the placebo group, but mild, dose-dependent increases were observed for
subjects receiving Compound A. Increases were observed at the first post-treatment time point,
and increased levels were maintained during the 2-week treatment period. sCr levels de‐
creased once treatment was discontinued. In nonclinical studies (rat and monkey) with
Compound A, there was no evidence of renal injury associated with sCr increases even when
elevated sCr levels were maintained for durations as long as 9 months. The time course and
magnitude of the sCr changes observed with Compound A are consistent with transporter
inhibition and have been observed for marketed drugs, such as cimetidine and trimethoprim.
For cimetidine, maximum inhibition of sCr secretion occurs within 24 hours after administra‐
tion and sCr levels return to baseline several days after discontinuation of dosing [62].
Figure 3. Temporal pattern of sCr changes in human subjects following 14 days oral administration of Compound A.
A proposed strategy for investigating increased sCr levels when inhibition of renal transport‐
er(s) is suspected is provided in Fig. 4. First, GFR should be determined with an alternative
method (e.g., measurement of serum levels of cystatin C) to rule out renal impairment as a
cause for the creatinine increase. Serum cystatin C is a more accurate biomarker for GFR
estimation because it is filtered in the glomeruli, but not secreted by renal transporters [55].
Other methods such as inulin [63] or radioisotopes also are available, but are impractical
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clinically as these methods can be costly and time-consuming and may delay clinical inter‐
vention. If the GFR measured with an alternative method remains suppressed, potential renal
injury can be investigated with various biomarkers (see Section 7). If GFR is not affected, then
OCT2 or MATE inhibition can be explored with an in vitro study. An IC50 in the range of
clinically relevant concentrations would support inhibition of renal transporters as the
mechanism for the sCr increase. Other mechanisms such as changes in sCr production (e.g.,
diet, disease status) would need to be explored if the sCr increase is not explained by inhibition
of renal transporters.
Figure 4. Strategy to investigate involvement of renal transporters in sCr changes.
Compound A was investigated with the described strategy (Fig. 4). Although sCr was
increased, GFR was not affected when calculated with serum cystatin C. Compound A was
then tested for OCT2 inhibition and shown to inhibit metformin uptake into CHO cells
expressing OCT2 in a concentration-dependent manner (Fig. 5). Concentrations of Compound
A were similar between the in vitro inhibition profile and human plasma concentrations where
sCr increases were observed. Based on these data, Compound A was considered to increase
sCr levels by inhibiting tubular secretion of creatinine via OCT2.
Similar to OCT2, elevation of sCr by a drug can also occur with the inhibition of MATE
transporters. For example, pyrimethamine, a potent inhibitor of MATE transporters and a
weak inhibitor of OCT2 [64], increased sCr within 28 h from 81 +/- 14 to 102 +/- 16 µM (P =
0.002) in the healthy volunteers [65]. Therefore, inhibition of MATE transporters should also
be considered to be a potential mechanism when increased levels of sCr are clinically-
associated with drug administration.
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7. Importance of biomarkers in renal safety assessment
While the aforementioned examples in this chapter show that concentrations of drug and/or
metabolites in tissues provide greater predictivity for toxicity compared to plasma, routine
tissue sampling is not generally feasible in clinical safety assessments. Biomarkers are impor‐
tant tools in renal safety assessment because they can provide early and non-invasive indica‐
tion of compound-induced toxicities. Regulatory agencies (i.e., United States Food & Drug
Administration, FDA; European Medicines Agency, EMA and/or Japanese Pharmaceuticals &
Medical Devices Agency, PMDA) have recognized the need for novel, qualified, translational
renal biomarkers [66-68]. Traditional renal biomarkers, sCr and BUN, used in both preclinical
and clinical settings lack both specificity and sensitivity. For example, increases in sCr and
BUN levels may reflect alteration in GFR that can occur with or without renal tubular pathol‐
ogy and increases in sCr and BUN are measureable 2-3 days after significant loss of renal
function because the kidney has a huge functional reserve [69, 70]. Increased sCr may be
predictive of kidney injury only when nearly half of the functional nephron capacity has been
lost and the kidneys are unable to regulate fluid and electrolyte homeostasis [71]. sCr may also
be elevated due to physiologic states unrelated to compound-induced nephrotoxicity such as
dehydration and muscle damage [68, 72].
To date, eight urinary rat renal biomarkers have been qualified by the Critical Path Institute’s
Predictive Safety Testing Consortium (PSTC), Nephrotoxicity Working Group [66, 67] and the
International Life Sciences Institute-Health and Environmental Safety Institute (ILSI-HESI),
Biomarkers of Nephrotoxicity Project Group [68] for monitoring compound-induced, pro‐
gressive renal injury in rats. The qualified rat renal biomarkers include urinary markers: kidney
injury molecule-1 (KIM-1), albumin, total protein, ß2-microalbumin, cystatin C, clusterin,
trefoil factor-3 (TFF-3) and renal papillary antigen-1 (RPA-1). These novel biomarkers are
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Figure 5. Inhibition of metformin uptake into CHO cells expressing OCT2 by Compound A. With CHO cells, stably
transfected with cDNA encoding for OCT2, transport of a prototypical substrate of OCT2, metformin (10 µM, 1 min)
was determined in the presence and absence of various concentrations of Compound A.
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highly sensitive, specific (show differential expression patterns within nephron segments), and
add to the diagnostic values of sCr and BUN.
The utility of these qualified rat urinary renal biomarkers include monitoring renal function,
tissue injury response and tissue leakage [72].  Functional  renal  biomarkers  are  used for
monitoring  changes  in  renal  physiology,  GFR  and/or  tubular  reabsorption  and  include
urinary total  protein [73-77],  albumin [75,  78,  79],  ß2-microalbumin [80],  and cystatin C.
High levels of proteins in urine (proteinuria) indicate progressive loss of renal function and
alterations  of  the  glomerular  filtration  barrier  such  as  damage  to  the  glomerular  podo‐
cytes or leakage of plasma proteins into the filtrate. Urinary albumin is synthesized in the
liver,  circulates  in  systemic  blood vessels,  and is  a  major  high molecular  weight  serum
protein larger  than the  pores  of  the  glomerular  filter.  Albumin is  normally  filtered and
absorbed by proximal tubule epithelium, degraded, and reutilized or excreted into the urine;
therefore,  the  appearance  of  albumin in  urine  represents  injury  to  the  glomerular  base‐
ment membrane [72]. Glomerular injury with subsequent impairment of tubular reabsorp‐
tion may be detected by urinary levels of ß2-microalbumin and cystatin C; which appear
to  be  more  reliable  than  traditional  renal  biomarkers,  sCr  and BUN [67].  The  gene  for
cystatin C is expressed in all nucleated cells and bears the characteristics of a housekeep‐
ing gene; therefore, cystatin C production rate is assumed to remain constant, a character‐
istic  which  lends  to  its  utility  in  the  clinic  as  an  endogenous  marker  of  GFR  [80].  ß2-
microalbumin is produced by mononulear cells which limits use as a GFR marker.
Urinary total protein, urinary albumin, urinary ß2-microalbumin and urinary cystatin C are
qualified for use in GLP rat studies to assess potential glomerular changes and/or impaired
tubular reabsorption [67]. When compound-induced tubular injury or glomerular alterations
have been identified in rat studies, urinary total protein, urinary albumin, urinary β2-
microglobulin and urinary cystatin C can be used as bridging biomarkers to monitor kidney
safety in clinical settings.
Renal tissue injury response biomarkers that have been qualified for monitoring compound-
induced renal injury in the rat include urinary KIM-1, urinary clusterin, urinary RPA-1 and
urinary TFF-3. Urinary KIM-1, also referred to as T-cell immunoglobulin mucin-1 (TIM-1) or
hepatitis A virus cellular receptor-1 (HAVCR-1) is expressed primarily but not exclusively in
proximal tubular epithelial cells and lymphocytes [81, 82]. KIM-1 mRNA and subsequently
KIM-1 protein is expressed during de-differentiation of proximal tubular epithelial cells.
KIM-1 has been reported to function as a receptor in the phagocytosis of apoptotic tubule
epithelial cells [82]. When KIM-1 protein is cleaved, the ectodomain is shed into the urine and
is stable at room temperature for several hours. KIM-1 has specificity and sensitivity for use
as a urinary biomarker to monitor compound-induced proximal tubular injury in rats. Similar
KIM-1 characteristics observed in the rat have been demonstrated in humans; and the cleaved
ectodomain of KIM-1 can be detected in the urine of patients with acute tubular necrosis;
therefore, urinary KIM-1 is also considered qualified as a clinical bridging biomarker to
monitor kidney safety in clinical studies on a “case-by-case” basis following the identification
of tubular injury in rats [82].
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Early detection and sensitivity of urinary KIM-1 as a biomarker of renal tubular injury were
demonstrated with a model of cisplatin-induced acute kidney injury (AKI) in male Sprague
Dawley rats treated for 1, 3, 5, 7, or 14 days at 1 mg/kg/day [83]. As early as 1 day after cisplatin
treatment, positive KIM-1 immunostaining, observed in the outer medulla of the kidney,
indicated the onset of proximal tubular injury in the absence of functional changes. After 3
days of treatment, KIM-1 protein levels in urine increased more than 20-fold concurrently with
tubular basophilia. After 5 days, sCr and BUN levels were elevated concurrently with tubular
degeneration. Cisplatin-induced increases in urinary and renal KIM-1 protein levels were
detected prior to changes in BUN, demonstrating the sensitivity of KIM-1 as a diagnostic tool
for detection of compound-induced proximal tubular injury in rats.
In another study in male Beagle dogs, KIM-1 was identified as a renal tissue injury response
marker (author’s unpublished data). Animals were intravenously administered cisplatin [0.75
mg/kg/day for up to 5 days) and humanely euthanized when sCr levels were ≥1.9 mg/dL,
indicating significant loss of GFR. AKI was histologically characterized by tubule dilatation,
vacuolization, degeneration, regeneration, and interstitial inflammation. Increased sCr was
not observed until approximately day 16 (Fig. 6], while increased urinary KIM-1 mRNA levels
were detected as early as Day 2 and were highly predictive of cisplatin-induced renal tissue
injury. KIM-1 protein expression was detected in the injured proximal tubular epithelial cells
(degenerated, vacuolized and dilated tubules) or regenerated proximal tubular epithelial cells
(tubular basophilia), primarily in the S2 segment correlated with histomorphologic changes
(Fig. 7). Neither urinary KIM-1 mRNA by quantitative polymerase chain reaction analysis nor
renal KIM-1 protein expression with immunostaining in canines with compound-induced AKI
has been previously reported.
Another renal injury biomarker, clusterin, exists as a secreted isoform or a nuclear isoform,
although only the 80 kDa glycosylated secreted isoform is constitutively expressed during
early stages of renal development and later in response to injury to proximal and distal tubules,
papillae, glomeruli, and collecting ducts [72, 81, 84, 85]. Secreted clusterin is believed to be
anti-apoptotic, and involved in lipid recycling, cell aggregation and cell attachment. Urinary
clusterin levels correlate with the severity of tubular damage [84]. In male Wistar rats, clusterin
mRNA was markedly induced and immunostaining demonstrated clusterin primarily in
tubules in the cortex and medulla following administration of puromycin aminonucleoside
(15 mg/100 g body weight, subcutaneously). Clusterin may differentiate between glomerular
and tubular injuries [84]. In a model of cisplatin-induced AKI in male Sprague Dawley rats,
urinary clusterin measurements were detected prior to changes in BUN [83]. Positive clusterin
immunostaining accurately correlated with the histopathologic findings. Urinary clusterin has
not been approved for clinical use [82].
Induction of RPA-1 expression correlates with immunoreactivity of inducible nitric oxide
synthase (iNOS) and nitrotyrosine. Thus, RPA-1 is believed to be increased in the cytoplasm
of intact cells of the collecting duct epithelium and proximal tubule epithelium following
compound-induced injury to nephron segments as a result of iNOS-dependent signal trans‐
duction pathways [72, 86]. Rat renal RPA-1 is highly expressed in the epithelial cells in
medullary (papilla) and cortical collecting ducts and in the medullary loop of Henle. In the rat,
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Figure 6. sCr and urinary KIM-1 (uKIM-1] mRNA measurements in dogs with cisplatin-induced AKI. (A) sCr increased
significantly in one dog on day 16. (B) Relative quantification of uKIM-1 mRNA levels in dogs with cisplatin-induced
AKI. Data are means ± SEM; a indicates P<0.001, b indicates P<0.01, and c and * indicate P<0.05 relative to predose
(Pre) values.
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urinary RPA-1 is the qualified diagnostic marker of choice for monitoring compound-induced
progressive renal papillary necrosis [50] and recovery [72]. TFF-3 is expressed in tubules of the
outer stripe of the outer medulla; urinary TFF3 protein levels are markedly reduced in response
to renal tubular injury [79]; however, TFF-3 may not outperform BUN and/or sCr to detect
kidney injury in rats [79]. Neither urinary RPA-1 nor urinary TFF-3 [79] has been qualified for
clinical use to date.
Tissue leakage markers: glutathione-S-transferase alpha (α-GST), glutathione-S-transferase-
mu (mu-GST/GSTYb1), and N-acetyl-β-D-glucosaminidase (NAG) are released from cells
upon structural damage to proximal tubular epithelium (rat α-GST) and distal tubular
epithelium (rat mu-GST) and reflect primarily tubular cell necrosis in various animal models
[83, 87, 88] and humans [89] where compound induced kidney injury was evident. Yet, α-GST,
mu-GST, and NAG have not been qualified; and their translational characteristics have not
been well defined to date.
In conclusion, the importance of biomarkers in renal safety assessment have been described
with emphasis on those biomarkers that have been qualified in rats and on a case-by-case basis
Figure 7. Representative hematoxylin and eosin-staining in a cisplatin-treated dog indicating tubular degeneration in
proximal tubules (c); representative cytoplasmic renal KIM-1 immunostaining in S2 segment proximal tubular epithe‐
lial cells (a, b and d).
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in the clinical setting [67]. Other potentially translational biomarkers of kidney injury have been
reported and are under consideration for qualification [90-92]. In addition, biomarkers specific
to a condition or disease are available. For example, erythropoietin (EPO) which is produced
primarily by fibroblast-like cortical interstitial cells in the kidney and functions to prevent
apoptosis of early erythroid precursor cells can be used as a biomarker for various conditions
of anemia [93], secondary forms of polycythemia [94], and abuse of erythropoiesis-stimulat‐
ing agents by athletes [95]. Another example is ferritin, a ubiquitous intracellular protein that
functions to store iron in a non-toxic form [96]. Serum ferritin levels correlate with total body
iron stores and is often used along with other iron tests as a biomarker for determination of
endogenous iron stores to aid diagnosis of disease including but not limited to iron deficien‐
cy anemia and acute renal failure [97] in patients with nephrohotic proteinuria likely due to
non-specific hepatic protein synthesis to compensate for loss of iron-binding transferrin [98].
8. Conclusions
Increased understanding of the effect of renal transporters on the distribution of a drug will
enhance safety assessment. Limiting the accumulation and/or distribution of a compound to
the kidney through selective interaction with renal transporters will potentially identify safer
drugs. Renal transporters also can be exploited as potential targets for therapeutic agents by
affecting the disposition of endogenous substrates. In the case of sCr, potential inhibition of
renal transporters can limit its utility as a safety biomarker. Whereas data are available for the
relationship between 8 qualified biomarkers that outperform sCr and/or BUN in monitoring
compound-induced renal injury in rats, the translation from rats to humans is limited by the
availability of qualified human biomarkers. Efforts are in progress to further assess the
translatability of urinary biomarkers in higher species including canines, non-human primates
and humans.
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